Win, Lose Or Yawn: Is Industry’s DTC Policy Working?
Executive Summary
Despite a strategic shift by industry curtailing playful ads and promotions in favor of a more serious clinical approach, the omission of risk information in advertising remains a pressing problem, FDA Division of Drug Marketing, Advertising & Communications Director Tom Abrams said
You may also be interested in...
AstraZeneca Takes Five: DTC Study Finds Five Risks Per Ad Is Optimal For Recall
An AstraZeneca study on consumer communication through direct-to-consumer television advertisements identifies five risks as the optimal number to include in order to ensure consumer recall of safety information
AstraZeneca Takes Five: DTC Study Finds Five Risks Per Ad Is Optimal For Recall
An AstraZeneca study on consumer communication through direct-to-consumer television advertisements identifies five risks as the optimal number to include in order to ensure consumer recall of safety information
Risk/Benefit “Fair Balance” In DTC Ads Leads To Confusion – Petition
FDA should redefine its policy of requiring "fair balance" of risk and benefit information in prescription drug advertising, the Coalition for Healthcare Communication says in a March 31 citizen petition